You searched for cancer - Page 3 of 469

Evaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2– metastatic breast cancer.

Posted by Medivizor on Apr 23, 2023 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC). The data showed that SG significantly improved survival without cancer progression compared to chemotherapy in these...

Evaluating the effects of aquatic physical therapy on fatigue symptoms and quality of life in patients with breast cancer.

Posted by Medivizor on Apr 15, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effects of aquatic physical therapy on improvement in fatigue symptoms and quality of life (QoL) in patients with breast cancer (BC). The data showed that aquatic physical therapy reduced fatigue symptoms and improved the QoL in women with BC. Some background Breast cancer (BC) is one of the most common...

Evaluating the effectiveness and safety of trifluridine-tipiracil plus bevacizumab in patients with resistant metastatic colorectal cancer

Posted by Medivizor on Mar 26, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of the combination of trifluridine-tipiracil (Lonsurf) and bevacizumab (Avastin) in patients with unresponsive (refractory) metastatic colorectal cancer (mCRC) in a real-world setting. The main finding was that trifluridine–tipiracil plus bevacizumab was safe and effective in...

Evaluating the effectiveness and safety outcomes of atezolizumab given before surgery in patients with non-small cell lung cancer.

Posted by Medivizor on Mar 26, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of atezolizumab (Tecentriq) given before surgery for the treatment of patients with non-small cell lung cancer (NSCLC). The data showed that atezolizumab given before surgery was safe and effective for patients with NSCLC. Some background Non-small cell lung cancer (NSCLC)...

Comparing darolutamide, apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Posted by Medivizor on Mar 26, 2023 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness of darolutamide (Nubeqa), apalutamide (Erleada), and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (nmCRPC). The data showed that darolutamide, apalutamide, and enzalutamide were similarly effective and improved survival outcomes compared to placebo...

Evaluating the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer.

Posted by Medivizor on Mar 24, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer. The data showed that most patients with breast and gynecological cancer developed antibodies after the second dose of the vaccine. However, the authors suggested that for non-responders or weak...

Evaluating the effectiveness and safety of oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer.

Posted by Medivizor on Mar 24, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of oral paclitaxel (Taxol) plus encequidar (HM 30181) versus intravenous (IV) paclitaxel in patients with metastatic breast cancer (BC). This study concluded that oral paclitaxel plus encequidar was more effective than IV paclitaxel with manageable side effects in these...

Evaluating the impact of fertility preservation on breast cancer and pregnancy outcomes in young women with breast cancer.

Posted by Medivizor on Mar 15, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the impact of fertility preservation with ovarian stimulation on breast cancer and pregnancy outcomes in young women with breast cancer (BC). The data showed that fertility preservation was safe and did impact BC outcomes. Some background Breast cancer (BC) is one of the most common cancers affecting women...

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Posted by Medivizor on Mar 5, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of cemiplimab (Libtayo) plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that cemiplimab plus chemotherapy as first-line treatment was effective with manageable side effects in these patients. Some...

Evaluating the effectiveness of chemotherapy before surgery for patients with colorectal cancer liver metastases.

Posted by Medivizor on Mar 5, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) for the treatment of patients with colorectal cancer liver metastasis (CRLM) at high risk. The data showed that NAC improved the overall survival of these patients. Some background Colorectal cancer (CRC) is one of the most common...

Evaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Posted by Medivizor on Mar 5, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of rezvilutamide (Ariane) versus bicalutamide (Casodex) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that rezvilutamide in combination with ADT significantly improved the...

Evaluating the role of radiotherapy in HER2+ early-stage breast cancer after breast-conserving surgery

Posted by Medivizor on Mar 5, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the effectiveness of radiotherapy (RT) in patients with HER2+ early-stage breast cancer (BC) after breast-conserving surgery (BCS). The study found that RT improved the survival rates of these patients, especially for those high-risk. Some background BC is categorized based on the absence or...

Evaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2– metastatic breast cancer.

Evaluating the effects of aquatic physical therapy on fatigue symptoms and quality of life in patients with breast cancer.

Evaluating the effectiveness and safety of trifluridine-tipiracil plus bevacizumab in patients with resistant metastatic colorectal cancer

Evaluating the effectiveness and safety outcomes of atezolizumab given before surgery in patients with non-small cell lung cancer.

Comparing darolutamide, apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer.

Evaluating the effectiveness and safety of oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer.

Evaluating the impact of fertility preservation on breast cancer and pregnancy outcomes in young women with breast cancer.

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Evaluating the effectiveness of chemotherapy before surgery for patients with colorectal cancer liver metastases.

Evaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Evaluating the role of radiotherapy in HER2+ early-stage breast cancer after breast-conserving surgery

Categories

Recent Posts

Archives

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email